Interplay between nanomedicine and protein corona
However, identifying your optimal medication reduces side effects and treatment errors, supporting overall safety
However, as with any treatment, there are potential side effects, such as swelling, bruising, or redness at the injection site, which typically subside quickly
Shashank Deshpande, Head of Human Pharma at Boehringer said: Survodutide has the potential to be the first global glucagon/GLP-1 dual agonist to help the more than 1 billion people living with obesity and MASH. Roche made headway earlier this year in advancing its injectable GLP-1/GIP receptor agonist CT-388 for obesity, while also demonstrating benefit for pre-diabetic patients
Diabetes mellitus and hypoglycemia